Urinary Tract Infection

Pivalic acid (Trimethylmethanecarboxylic acid) is a carboxylic acid. Pivalic acid induces Carnitine deficiency. Pivalic acid conjugated with Antibiotics, such as Pivmecillinam (HY-B0810) and Pivampicillin (HY-119011), are used in urinary tract infection. Pivalic acid can be used in physical exercise research.

Picotamide is an orally active TXA₂ receptor and TXA₂ synthase inhibitor. Picotamide inhibits ADP (HY-W010918)-, Arachidonic acid (HY-109590)-, and Collagen (HY-NP003)-induced platelet aggregation, reduces TXA₂ production during coagulation, and does not inhibit PGI2 synthesis in endothelial cells. Picotamide inhibits contractions induced by α1-adrenergic receptor agonism, TXA2 mediation, and neurogenic (electrical field stimulation-induced) factors in human prostatic smooth muscle, and broadly inhibits agonist-induced contractions of porcine interlobar renal and coronary arteries. Picotamide can be used in research related to thromboembolic diseases, atherosclerosis, and lower urinary tract symptoms.

5-(3',4'-Dihydroxyphenyl)-γ-valerolactone is an intestinal microbiota metabolite of (-)-Epicatechin (HY-N0001). 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone downregulates TNF-α-stimulated phosphorylation of IKK and IκBα, inhibits the transcriptional activation of NF-κB, and suppresses the expression of adhesion molecules and chemokines. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone promotes autophagy, alleviates oxidative stress, maintains osteoblast differentiation, induces G₁ phase arrest, inhibits adipogenesis, and scavenges ABTS free radicals. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone inhibits the adhesion of uropathogenic Escherichia coli to bladder epithelial cells; when used in combination with Curcumin (HY-N0005), it downregulates the NLRP3 and NOX2/Nrf2 signaling pathways, thereby reducing microglial activation. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone can be used in research related to diabetes, atherosclerosis, osteoporosis, obesity, neurodegenerative diseases involving microglial activation, and urinary tract infections.

Picotamide monohydrate is an orally active TXA₂ receptor and TXA₂ synthase inhibitor. Picotamide monohydrate inhibits ADP (HY-W010918)-, Arachidonic acid (HY-109590)-, and Collagen (HY-NP003)-induced platelet aggregation, reduces TXA₂ production during coagulation, and does not inhibit PGI2 synthesis in endothelial cells. Picotamide monohydrate inhibits contractions induced by α1-adrenergic receptor agonism, TXA2 mediation, and neurogenic (electrical field stimulation-induced) factors in human prostatic smooth muscle, and broadly inhibits agonist-induced contractions of porcine interlobar renal and coronary arteries. Picotamide monohydrate can be used in research related to thromboembolic diseases, atherosclerosis, and lower urinary tract symptoms.